A&O Shearman Advises GSK on USD2.2 Billion Acquisition of RAPT Therapeutics
January 23, 2026
January 23, 2026
LONDON, England, Jan. 23 -- A and O Shearman, a law firm, issued the following news:
* * *
A&O Shearman advises GSK on USD2.2 billion acquisition of RAPT Therapeutics
A&O Shearman is advising GSK plc (LSE/NYSE: GSK) on its definitive agreement to acquire RAPT Therapeutics (NASDAQ: RAPT), a California-based, clinical-stage biopharmaceutical company, for an estimated equity value of USD2.2bn.
The acquisition includes ozureprubart, a pote . . .
* * *
A&O Shearman advises GSK on USD2.2 billion acquisition of RAPT Therapeutics
A&O Shearman is advising GSK plc (LSE/NYSE: GSK) on its definitive agreement to acquire RAPT Therapeutics (NASDAQ: RAPT), a California-based, clinical-stage biopharmaceutical company, for an estimated equity value of USD2.2bn.
The acquisition includes ozureprubart, a pote . . .